Pelion

Pelion's activities

News

Q1 2009 results

In Q1 2009, Polska Grupa Farmaceutyczna posted consolidated net profit of PLN 13.3m and revenues in excess of PLN 1.37bn, thus recording its best ever quarterly sales figure, up by 1.2% year on year.

”In July 2008, the process of separating the retail business from PGF was completed. The simplification of the Group’s structure and development of services tailored to the needs of final user enabled us to optimise internal processes and promptyly respond to rapid changes in the marketplace,” – says Jacek Szwajcowski, President and CEO of PGF. ”W wyniku restrukturyzacji PGF stworzyła solidne podstawy do budowania przyszłej wartości firmy”.

The Group’s core business consists of four key segments:

  • Services for patients: retail sales and pharmaceutical care through the network of Company’s own, franchised and partner pharmacies, including a total of 2,300 outlets, which in Poland operate under the name of APTEKI Dbam o zdrowie and in Lithuania – under the Gintarine Vaistine and Norfos Vaistine brands;
  • Services for pharmacies: a portfolio of 25 thousand pharmaceuticals supplied to over 10,000 pharmacies from 14 warehouses operating under the PGF brand in Poland and the Limedika brand in Lithuania;
  • Services for hospitals: supplies of pharmaceuticals and financial services under the Urtica and PGF brands;
  • Services for producers: logistics services (including direct distribution), financial services, call centre support and marketing services.
    The Group is also developing support services in these key segments (financial and accounting functions, receivables management and real estate management), and is engaged in other activities through such companies as Pharmena S.A. or ePRUF S.A.

    In H2 2008, PGF launched a new, innovative system of product sales to pharmacies, known as GRA (Grupa Rabatowo-Asortymentowa – Discount and Product Portfolio Group). The project’s objective was to implement a simple and transparent sales system open to all market players: producers, wholesalers, pharmacies and thus also patients. “By introducing the new sales policy we intended to cater to the interests of all parties involved in the trade in pharmaceuticals and to respond to the emerging need to rationalise the processes in the sector,” – sums up Mr Szwajcowski. “First results of the implementation of the GRA project are already visible. Those pharmacies which use all features offered by the system have enjoyed a quicker pace of development than their competitors; producers may agree with wholesalers cost of services offered, depending on the extent of such services; and patients have access to cheaper pharmaceuticals”.

    PGF has also identified an enormous potential of Internet-based solutions. The Doz.pl portal and its in-built Internet pharmacy offers patients pharmaceutical e-care, access to cheapest pharmaceuticals, ability to consult pharmacists. eFarmtargi.pl and eMedicines are used by pharmacies as a supplement to traditional tools of promotion and sales.

    On May 9th 2009, PGF launched a system supporting direct sales of AstraZenceca products. Poland is among the first markets in the world where such a solution has been implemented. Under the project, PGF offers extremely high standard of services for all pharmacies in Poland.

    Polska Grupa Farmaceutyczna works with practically all pharmaceutical producers present in Poland and Lithuania. In addition to the management of supply chain and financial and administrative services, PGF also offers a broad range of sales support services. PGF S.A.’s call center, a separate function within the organisation, provides telesales services to producers (including product promotional campaigns, marketing of new products, comprehensive market research, informational and promotional campaigns, as well as infoline outsourcing).

    Consolidated financial results of Polska Grupa Farmaceutyczna

      Q1 2009 I Q1 2008 Change
    EBITDA (PLN ‘000) 36 769 34 583 +6,3%
    EBITDA margin (%) 2,69 2,56 +0,13 p.p
    Operating profit (PLN ‘000) 29 337 28 670 +2,3%
    Net profit attributable to equity holders of the parent (PLN ‘000) 13 337 19 386 -31,2%
    Net margin (%) 0,97 1,43 -0,46 p.p.

Please note that Pelion S.A. uses cookies on its website. Click I Agree and this information will not be shown again. Click on the Privacy Notice to find out more, including how to manage cookies through your browser settings.

I agree